Accelerating and improving outcomes of gene therapy projects from DNA design to commercial scale

We are a science-driven CDMO offering unique expertise in viral vector design and manufacturing, with leading and internationally renowned experts.

DINAMIQS at a glance

View our flyer

Unique customer experience

  • For us, your project is much more than a number– and that sets us apart from larger CDMOs
  • We have a demonstrated track record where others have been unsuccessful
  • We focus on science, innovation and technology to increase the probability of success early on in your project

Fully integrated CDMO, tailored to your needs

  • We provide top-scientific advice and consulting from our experts regardless of the stage of your project
  • We de-risk and accelerate your pipeline with continuous product development support
  • We incorporate GMP-compatible processes from early phase, reducing efforts, time and costs
  • We deliver R&D-grade and preclinical batches
  • We perform cutting edge integrated analytical services
  • Our cGMP facility with integrated fill and finish capacities is in construction

Swiss quality, in a global network

  • Our site is located in Switzerland, in Zurich’s Bio-Technopark
  • Our team consists of leading international scientists and experts
  • We provide a global service, leveraging full access to Siegfried’s network of 13 global sites

Tackling challenges in viral vector manufacturing

Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at commercial scale is still a limitation to its broader use. Dr. Eduard Ayuso discusses how DINAMIQS works to overcome these challenges.

Read more

News

Update May 04, 2024
Celebrating 1 year as Siegfried DINAMIQS
Update Mar 01, 2024
DINAMIQS welcomes new CEO
Media release Feb 02, 2024
DINAMIQS Appoints New CEO and Board Member
Update Jan 18, 2024
DINAMIQS welcomes two new leadership team members
Update Dec 27, 2023
Newly launched website for Magic Horizon
Update Dec 19, 2023
Successful implementation of the Stunner
Update Dec 11, 2023
Implementing the SamuxMP mass photometer
Update Nov 06, 2023
We are open for partnerships
Update Sep 26, 2023
Setting up the AKTA Avant
Update Sep 21, 2023
Reaching a next milestone
Media release May 24, 2023
Siegfried acquires majority stake in DINAMIQS to establish a best-in-class development and manufacturing organization for cell and gene therapies

Contact

Let's get in touch

Martin Kessler
Chief Executive Officer
Vincent Zuliani
Head of Business Development
To top